4-溴-2-萘甲醛 | 874357-11-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4-溴-2-萘甲醛
• 英文名称: 4-bromo-naphthalene-2-carbaldehyde
• 英文别名: 4-Bromo-2-naphthaldehyde；4-bromonaphthalene-2-carbaldehyde
• CAS: 874357-11-6
• 化学式: C₁₁H₇BrO
• 分子量: 235.08
• InChiKey: XXBWXFQJIKOIKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-溴-2-萘甲醛 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.58h， 以90%的产率得到(4-Bromonaphthalen-2-yl)-(5-ethylbenzo-[b]thiophen-2-yl)methanol
  参考文献：
  名称：

  EP1803721

  摘要：

  公开号：
• 作为产物：
  描述：

  (4-溴-萘-2-基)-甲醇 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.92h， 以78%的产率得到4-溴-2-萘甲醛
  参考文献：
  名称：

  EP1803721

  摘要：

  公开号：

文献信息

• HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS
  申请人：THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  公开号：US20160168140A1

  公开（公告）日：2016-06-16

  The invention relates to heterocyclic compounds and their use as antibiotics and/or as antibiotic potentiators. The compounds may act as colistin potentiators and SOS inhibitors.

  这项发明涉及杂环化合物及其作为抗生素和/或抗生素增效剂的用途。这些化合物可能作为科利斯汀增效剂和SOS抑制剂起作用。
• Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080319047A1

  公开（公告）日：2008-12-25

  The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R 1 to R 4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

  本发明提供了一种葡萄糖醇衍生物，具有降低血糖水平的功能，并具有药物所需的优良性质，例如持久的药物活性；以及用于预防或治疗由高血糖引起的疾病，例如糖尿病、糖尿病并发症和肥胖症的药物组合物。该衍生物是由式(I)表示的化合物：其中m是在1-3之间选择的整数；R1至R4各自独立地是可选的取代烷基等；Ar1是可选的取代萘基；A是可选的取代杂环芳基、该化合物的前药或其药学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US07943748B2

  公开（公告）日：2011-05-17

  The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

  本发明提供了一种葡萄糖醇衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，例如长效药物活性；以及用于预防或治疗由高血糖引起的疾病，例如糖尿病、糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：其中m是在1-3之间选择的整数；R1到R4各自独立地是可选的取代烷基等；Ar1是可选的取代萘基；A是可选的取代杂环基，该化合物的前药物或其药学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• 一种Kras抑制剂及其制备方法
  申请人：上海拓界生物医药科技有限公司

  公开号：CN115197245A

  公开（公告）日：2022-10-18

  本公开涉及一种Kras抑制剂及其制备方法。具体而言，本公开涉及一种式I所示的化合物或其药学上可接受的盐，本公开还涉及组合物及其医药用途，具体取代基的定义如说明书中所述。
• A composition for increasing the anti-cancer activity of an anti-cancer compound
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0180188A2

  公开（公告）日：1986-05-07

  A composition for increasing the anti-cancer activity of an anti-cancer compound selected from among 5-fluorouracil and a compound capable of producing 5-fluorouracil in vivo, the composition comprising an effective amount of a pyridine derivative represented by the formula wherein R1 is hydroxy or acyloxy, R2 and R4 are each hydrogen, halogen, amino, carboxyl, carbamoyl, cyano, nitro, lower alkyl, lower alkenyl or lower alkoxycarbonyl, R3 and R are each hydrogen, hydroxy or acyloxy; when at least one of R1, R3 and R5 is hydroxy, the structure of 1-position on the pyridine rina can be duetothe due to the keto-enol tautomerism, said hydrogen attached to nitrogen being optionally substituted with a substituent selected from the group consisting of lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, phthalidyl, carbamoyl, lower alkoxycarbonyl-lower alkylcarbamoyl, phenyl-lower alkoxy-lower alkyl, phenylcarbamoyl which may have a substituent on the phenyl ring, lower alkylcarbamoyl, carboxy-lower alkylcarbamoyl, lower alkylthio-lower alkyl and lower alkenyl, provided that the compound having the following formula is excluded, wherein a is hydrogen, lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, lower alkylcarbamoyl, lower alkylthio-lower alkyl or lower alkenyl.

  一种提高选自5-氟尿嘧啶和一种能在体内产生5-氟尿嘧啶的化合物的抗癌活性的组合物，该组合物包括有效量的由式表示的吡啶衍生物 其中 R1 是羟基或酰氧基，R2 和 R4 分别是氢、卤素、氨基、羧基、氨基甲酰基、氰基、硝基、低级烷基、低级烯基或低级烷氧基羰基，R3 和 R 分别是氢、羟基或酰氧基；当 R1、R3 和 R5 中至少有一个是羟基时，吡啶里纳上 1 位的结构可以是 当 R1、R3 和 R5 中至少有一个是羟基时，吡啶里纳上 1 位的结构可以是酮烯醇同分异构，所述连接到氮上的氢可选择被选自低烷基、四氢呋喃基、四氢吡喃基、低烷氧基低烷基、邻苯二甲酰基、氨基甲酰基、低烷氧基羰基低烷基氨基甲酰基组成的取代基取代、苯基-低级烷氧基-低级烷基、苯基氨基甲酰基（苯基环上可能有取代基）、低级烷基氨基甲酰基、羧基-低级烷基氨基甲酰基、低级烷硫基-低级烷基和低级烯基，但具有下式的化合物除外、 其中 a 为氢、低级烷基、四氢呋喃基、四氢呋喃基、低级烷氧基低级烷基、低级烷基氨基甲酰基、低级烷硫基低级烷基或低级烯基。